Abstract:ObjectiveAberrant epigenetic remodeling represents a molecular hallmark in lung adenocarcinoma (LUAD). We aim to investigate the biological roles of SETDB2 and its underlying associations with oxidative stress, providing therapeutic targets for individualized treatment of LUAD. MethodsDifferential analysis was conducted via Limma package, and Kaplan-Meier analysis was performed with survival package. CCK-8, cell proliferation assay, transwell assay, and in vivo assays were conducted to assess the function of SETDB2. Western blot assay, RT-qPCR, and immunohistochemistry (IHC) were conducted to assess the expression levels of SETDB2/NRF2. Chromatin immunoprecipitation (ChIP) assay and ChIP-qPCR were conducted to assess the epigenetic roles of SETDB2. ResultsWe found that SETDB2 expression is decreased in tumor samples versus normal tissues in TCGA-LUAD cohort, LUAD-EAS cohort, GSE72094 dataset, and independent Soochow-LUAD dataset. Patients with low SETDB2 levels had a worse prognosis relative to those with high SETDB2. SETDB2 inhibition could significantly promote cell growth, migration ability, and stemness maintenance. Gene set enrichment analysis (GSEA) suggested that SETDB2 correlated with oxidative stress crosstalk and regulated NRF2 mRNA levels. ChIP assay suggested that SETDB2 mainly recruited the H3K9me3 enrichment at the NRF2 promoter region to suppress the mRNA levels of NRF2. Downregulated SETDB2 could activate NRF2 transcription and expression, thereby promoting its downstream targets, like NQO1, FTH1, and ME1. Functional experiments demonstrated that low SETDB2 allowed NRF2 to drive malignant processes of LUAD. SETDB2 overexpression attenuated the ability of NRF2 signaling to neutralize cellular reactive oxygen species (ROS) levels, leading to enhanced cell apoptosis. Overexpressed SETDB2 could inhibit tumor progression in vivo and further render LUAD cells sensitive to chemotherapy. ConclusionsIn conclusion, these findings uncovered the suppressive role of SETDB2 in LUAD. SETDB2 negatively regulates NRF2 signaling to modulate tumor progression, which creates a therapeutic vulnerability in LUAD.

Histone Lysine Methyltransferase SETDB2 Suppresses NRF2 to Restrict Tumor Progression and Modulates Chemotherapy Sensitivity in Lung Adenocarcinoma

Histone Methyltransferase SETD2 Inhibits Tumor Growth Via Suppressing CXCL1-mediated Activation of Cell Cycle in Lung Adenocarcinoma

MTHFD2 Promotes Tumorigenesis and Metastasis in Lung Adenocarcinoma by Regulating AKT/GSK‐3β/β‐catenin Signalling

Methyltransferase SETD2 Inhibits Tumor Growth and Metastasis via STAT1‐IL‐8 signaling mediated EMT in lung adenocarcinoma

SETD2 Regulates Gene Transcription Patterns and is Associated with Radiosensitivity in Lung Adenocarcinoma

Methyltransferase SETD2 inhibits tumor growth and metastasis via STAT1–IL‐8 signaling‐mediated epithelial–mesenchymal transition in lung adenocarcinoma

SETD2 Mediates Immunotherapy and Radiotherapy Efficacy Via Regulating DNA Damage Responses and Genomic Stability in Lung Adenocarcinoma

CBX2 and EZH2 Cooperatively Promote the Growth and Metastasis of Lung Adenocarcinoma

SETD4 Confers Cancer Stem Cell Chemoresistance in Nonsmall Cell Lung Cancer Patients Via the Epigenetic Regulation of Cellular Quiescence

SMC2 knockdown inhibits malignant progression of lung adenocarcinoma by upregulating BTG2 expression

Histone Methyltransferase SETD2: a Potential Tumor Suppressor in Solid Cancers

Ferroptosis Regulator FANCD2 is Associated with Immune Infiltration and Predicts Worse Prognosis in Lung Adenocarcinoma

Investigating the Functional Role of SETD6 in Lung Adenocarcinoma

Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma

NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis

Methyl-CpG Binding Domain Protein 2 Inhibits the Malignant Characteristic of Lung Adenocarcinoma Through the Epigenetic Modulation of 10 to 11 Translocation 1 and Mir-200S.

ESCO2 promotes lung adenocarcinoma progression by regulating hnRNPA1 acetylation

Setdb1 Accelerates Tumourigenesis by Regulating the Wnt Signalling Pathway

CKS2 Overexpression Correlates with Prognosis and Immune Cell Infiltration in Lung Adenocarcinoma: A Comprehensive Study Based on Bioinformatics and Experiments

High ECT2 Expression is an Independent Prognostic Factor for Poor Overall Survival and Recurrence-Free Survival in Non-Small Cell Lung Adenocarcinoma

Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development.